Categories
Change Password!
Reset Password!
Tegoprazan, when used as on-demand therapy, offers quicker symptom improvement for GERD than Esomeprazole.
According to the outcomes of a randomized controlled trial, on-demand Tegoprazan therapy provides faster symptom relief than traditional proton-pump inhibitors (PPIs) like Esomeprazole in patients suffering from gastroesophageal reflux disease (GERD). Researchers sought to compare Tegoprazan with Esomeprazole for maintenance treatment in GERD sufferers whose symptoms had improved with acid-suppressive therapy.
Conducted across 6 hospitals, the trial involved 69 participants who were randomly assigned to receive either 50 mg Tegoprazan + placebo Esomeprazole or placebo Tegoprazan + Esomeprazole 20 mg. The key endpoint was patient satisfaction with the on-demand treatment, estimated on a 5-point Likert scale after 8 weeks. Results showed no prominent difference in satisfaction between the Tegoprazan (4.31) and Esomeprazole (4.15) groups.
However, a higher proportion of Tegoprazan-treated patients experienced faster symptom improvement within 30 minutes when compared to Esomeprazole-treated patients, as shown in Table 1:
Additionally, the Tegoprazan group exhibited a markedly shorter time to symptom improvement overall. Importantly, no serious adverse events were reported, confirming Tegoprazan's safety for on-demand therapy in GERD. Hence, Tegoprazan (potassium-competitive acid blocker, P-CAB) offers a promising alternative to traditional PPI therapy, with quicker symptom relief and similar patient satisfaction.
Scientific Reports
Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial
Sun Hyung Kang et al.
Comments (0)